Rosalind Advisors
TORONTO, A6files as Rosalind Advisors, Inc.
$266m in 29 US stocks at the end of 30 June 2026. The top 10 are 74.9% of the money. It changed about 17.2% of the portfolio this quarter.
Value
$266m
Stocks
29
Top 10 share
74.9%
Turnover
17.2%
What changed this quarter
New
Bought for the first time this quarter.
- Abivax SAABVX1.0% of the fund
- Spruce BiosciencesSPRB0.4% of the fund
- PepGenPEPG0.2% of the fund
Added
Bought more of a stock they already held.
- Fennec PharmaceuticalsFENC12.9% of the fund+10%
- VerastemVSTM5.7% of the fund+86%
- Helus PharmaHELP4.9% of the fund+28%
- TalpheraTLPH2.0% of the fund+54%
- NeuraxisNRXS1.1% of the fund+78%
- Regentis BiomaterialsRGNT0.9% of the fund+179%
- BiofronteraBFRI0.5% of the fund+10%
Cut
Sold some of their stake.
- Xeris Biopharma HoldingsXERS8.7% of the fund-10%
- EyePointEYPT5.3% of the fund-5%
- Vor BiopharmaVOR4.5% of the fund-7%
- VaxcytePCVX4.4% of the fund-31%
- Celldex TherapeuticsCLDX2.8% of the fund-39%
- Biocryst PharmaceuticalsBCRX2.7% of the fund-22%
- Atea PharmaceuticalsAVIR1.9% of the fund-9%
- MyomoMYO1.4% of the fund-5%
- PolyPidPYPD0.7% of the fund-35%
- OnKure TherapeuticsOKUR0.3% of the fund-66%
Sold out
Sold their entire stake.
- CG OncologyCGON-100%
- Viridian TherapeuticsVRDN-100%
- Definium TherapeuticsDFTX-100%
- LipocineLPCN-100%
- Avalo TherapeuticsAVTX-100%
- AnnexonANNX-100%
Holdings
- Helus PharmaHELP
- Share
- 4.9%
- Value
- $13m
- Shares
- 1,956,814
+28%
- Abivax SAABVX
- Share
- 1.0%
- Value
- $3m
- Shares
- 20,869
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Delcath SystemsDCTH | 15.6% | $42m | 3,300,389 | Held |
| Fennec PharmaceuticalsFENC | 12.9% | $34m | 3,188,001 | +10% |
| Xeris Biopharma HoldingsXERS | 8.7% | $23m | 2,908,981 | -10% |
| SavaraSVRA | 7.4% | $20m | 3,178,121 | Held |
| VerastemVSTM | 5.7% | $15m | 3,986,509 | +86% |
| X4 PharmaceuticalsXFOR | 5.6% | $15m | 3,214,766 | Held |
| EyePointEYPT | 5.3% | $14m | 988,230 | -5% |
| Helus PharmaHELP | 4.9% | $13m | 1,956,814 | +28% |
| Vor BiopharmaVOR | 4.5% | $12m | 648,600 | -7% |
| VaxcytePCVX | 4.4% | $12m | 200,000 | -31% |
| MediWoundMDWD | 4.1% | $11m | 749,054 | Held |
| Celldex TherapeuticsCLDX | 2.8% | $7m | 200,000 | -39% |
| Biocryst PharmaceuticalsBCRX | 2.7% | $7m | 721,504 | -22% |
| Profound MedicalPROF | 2.1% | $6m | 828,118 | Held |
| TalpheraTLPH | 2.0% | $5m | 5,169,501 | +54% |
| Atea PharmaceuticalsAVIR | 1.9% | $5m | 1,070,550 | -9% |
| MyomoMYO | 1.4% | $4m | 3,637,886 | -5% |
| Ovid TherapeuticsOVID | 1.1% | $3m | 1,107,994 | Held |
| NeuraxisNRXS | 1.1% | $3m | 508,055 | +78% |
| Abivax SAABVX | 1.0% | $3m | 20,869 | New |
| InspireMDNSPR | 1.0% | $3m | 3,905,743 | Held |
| Regentis BiomaterialsRGNT | 0.9% | $2m | 701,685 | +179% |
| PolyPidPYPD | 0.7% | $2m | 389,455 | -35% |
| BiofronteraBFRI | 0.5% | $1m | 1,275,609 | +10% |
| Kura OncologyKURA | 0.4% | $1m | 100,000 | Held |
| Spruce BiosciencesSPRB | 0.4% | $1m | 20,000 | New |
| Aquestive TherapeuticsAQST | 0.4% | $1m | 250,000 | Held |
| OnKure TherapeuticsOKUR | 0.3% | $684,000 | 150,000 | -66% |
| PepGenPEPG | 0.2% | $630,000 | 350,000 | New |
Options (6)
- Sellas Life Sciences Group I
- Type
- Put
- Value
- $2m
- Contracts
- 568,700
- CG Oncology
- Type
- Call
- Value
- $375,100
- Contracts
- 31,000
- Eyepoint
- Type
- Call
- Value
- $130,780
- Contracts
- 50,300
- Ishares TR
- Type
- Put
- Value
- $110,000
- Contracts
- 500,000
- Spdr Series Trust
- Type
- Put
- Value
- $35,150
- Contracts
- 140,600
- Tenax Therapeutics
- Type
- Put
- Value
- $13,950
- Contracts
- 6,200
| Company | Type | Value | Contracts |
|---|---|---|---|
| Sellas Life Sciences Group I | Put | $2m | 568,700 |
| CG Oncology | Call | $375,100 | 31,000 |
| Eyepoint | Call | $130,780 | 50,300 |
| Ishares TR | Put | $110,000 | 500,000 |
| Spdr Series Trust | Put | $35,150 | 140,600 |
| Tenax Therapeutics | Put | $13,950 | 6,200 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 28.8% since 30 June 2025.
Where the money is
Health care99.0%
Other1.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.